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Received 15 January 2003; revised 31 March 2003; accepted 24 April 2003Abstract—Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-amino-
piperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new com-
pounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the
cognitive deficit produced by neurodegenerative pathologies like Alzheimer’s disease.
# 2003 Elsevier Science Ltd. All rights reserved.Cognitive dysfunction is one of the main symptoms
accompanying ageing, stroke, head injury and neuro-
degenerative diseases like Alzheimer’s disease. Cogni-
tion enhancers,1 often referred to as nootropics, can be
defined as drugs able to facilitate attentional abilities
and acquisition, storage and retrieval of information,
and to attenuate the impairment of cognitive functions
associated with age and age-related pathologies.2 By
definition, this class of drugs improves declining of
cognitive functions but does not change the rate of
progression of neurodegeneration.3
Recently, we described a new class of compounds with a
1,4-diazabicyclo[4.3.0]nonan-9-one structure4 (Chart 1)
that showed a very potent cognition enhancing activity
on mouse passive avoidance assay. These compounds
were related to the family of piracetam-like
nootropics1,57 by the presence of the 2-pyrrolidinone
ring. However, high activity was maintained when the
2-pyrrolidinone ring was opened to give the corre-
sponding piperazine derivatives8 (Chart 1), suggesting
that in this class of compounds the 2-oxopyrrolidine
moiety is not critical for pharmacological action. Both
series of compounds were effective also in other beha-
vioural tests such as social learning and Morris water
maze.810Continuing to explore structure–activity relationships
in the series of piperazine compounds, we have
designed a new series of compounds carrying a
4-aminopiperidine ring. Formally, they can be con-
sidered analogues where one of the nitrogen atoms of
piperazine has been moved out of the six-member cycle
(Chart 2). Besides the side chains that were present in
the leads DM232 and DM235, we have added the iso-
propylsulfonyl group, present in a series of compounds
active as allosteric modulators of AMPA receptor.11,12
As a matter of fact, an ongoing research aimed to
define the mechanism of action of DM232, DM235
and related compounds seems to suggest the involve-
ment of AMPA receptors. (C. Ghelardini, personal
communication).
Compounds 5, 6, 11 and 12 have been synthesised as
shown in Scheme 1. 1-Acetyl-4-piperidone and 1-ben-
zoyl-4-piperidone, commercially available, and 1-pro-
pionyl-4-piperidone (17), obtained from 4-piperidone
monohydrate hydrochloride with propionyl chloride,
were transformed in 18–20 by reductive alkylation
with benzylamine, titanium(IV) isopropoxide and
sodium cyanoborohydride.13 The compounds were
then hydrogenated14 to obtain 21–23. Compound 2315
was treated with acetyl or propionyl chloride to
obtain 5 and 6 respectively, while 2116 and 22 were
treated with 4-fluorobenzenesulfonyl chloride to give
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The synthetic pathways used to obtain compounds 7–10
and 13–16 are reported in Scheme 2. Commercially
available 4-amino-1-benzylpiperidine was treated with
the proper acyl chloride or isopropylsulfonyl chloride;
the intermediates 24,18 25,19 2620 and 30 were then
hydrogenated to give 27,21 28,22 2923 and 31. Inter-
mediates 27 and 28 were treated with 4-fluoro-
benzenesulfonyl chloride24 to give 9 and 10 and with
isopropylsulfonyl chloride to give 13 and 14, whereas 29
was treated with acetyl or propionyl chloride to give 7
and 8. Finally, reaction of 31 with acetyl or propionyl
chloride gave 15 and 16 respectively. Chemical and
physical characteristics of compounds 5–16 are reported
in Table 1.
Cognition enhancing activity was evaluated by the anti-
amnesic test (mouse passive-avoidance test). The test
was performed according to the step-through method
described by Jarvik and Kopp,25 slightly modified by
us.4,26 In short, mice receive a punishment when enter-
ing a dark room in the training session and remember it
in the session of the following day, unless their memory
is impaired by the amnesic drug. The parameter mea-
sured is the entry latency time (expressed in seconds)
occurring between the time the mouse is placed in the
light and the time it enters the dark room. On the first
day there is the training session, while on the second day
the mice are placed again in the light and the new
latency time is measured on animals treated or
untreated with the nootropic drug. A drug is active
when, at a given dose, it restores in the scopolamine-
treated mice the retention time of those treated only
with saline. The highest active doses of the investigatedChart 1.Chart 2.Scheme 1. (a) CH3CH2COCl, K2CO3, CHCl2 60
C: 17, 72%; (b)
benzylamine, (iPrO)4Ti, NaBH3CN, EtOH: 18, 85%, 19, 68%, 20,
26%; (c) HCOONH4, Pd/C 10%, MeOH: 21, 74%, 22, 97%, 23, 75%;
(d) CH3COCl, NaHCO3, CHCl3: 5, 45%, CH3CH2COCl, N(Et)3,
CHCl3: 6, 94%; (e) 4-F-benzenesulfonyl chloride, N(Et)3, CH3CN: 11,
86%, 12, 82%.Scheme 2. (a) XCOCl, NaHCO3, CHCl3: 24, 79%, 25, 99%, NEt3,
CHCl3: 26, 99%, 15, 55%, 16, 42%; (b) HCOONH4, Pd/C 10%,
MeOH: 27, 98%, 28, 73%, 29, 88%, 31, 50%; (c) isopropylsulfonyl
chloride, N(Et)3, CH3CN: 30, 57%; (d) 4-F-benzenesulfonyl chloride
or isopropylsulfonyl chloride, N(Et)3, CH3CN: 9, 59%, 10, 84%, 13,
43%, 14, 76%; (e) XCOCl, N(Et)3, CHCl3: 7, 47%, 8, 97%.2304 D. Manetti et al. / Bioorg. Med. Chem. Lett. 13 (2003) 2303–2306
compounds did not altered animals’ gross behaviour
and were devoid of any behavioural side effect, as
demonstrated by the Irwing test.27 The results obtained
with the new molecules are reported in Table 2, com-
pared with those of the parent compounds 1–4.The data reported show that the new series of com-
pounds maintains potent cognition enhancing activity,
being effective at doses between 0.01 and 10 mg/kg ip,
while a typical nootropic drug like piracetam, under the
same conditions in experiments performed in parallel
with our compounds, is active at a dose of 30 mg/kg ip.8
In particular, compound 9 is active at a dose of 0.01 mg/
kg ip, which is in the same range of that of DM 235, the
most potent among the parent compounds.8 Therefore,
it may be concluded that transforming the piperazine
moiety into a 4-aminopiperidine one does not alter the
pharmacological behaviour of the original compounds.
In the new series, the two nitrogen atoms are not
equivalent and two regio-isomers are possible for each
couple of substituents. Overall, the regio-isomers show
similar potencies as cognition enhancers. In this respect,
the isomers bearing the aromatic substituents on the
piperidine nitrogen seem to be slightly more potent
(compare 9/11, 10/12, 13/15) than their counterparts,
even if the reverse is true for the couple 5/7 and the
couples 6/8 and 14/16 show the same potency. Finally,
the introduction of the isopropylsulfonic group did not
produce remarkable results, even if compound 13 was
found active at the dose of 1 mg/kg ip.
In conclusion, we have identified a new class of potent
cognition enhancing drugs, among which compound 9
deserves further study and can be a useful new lead to
develop drugs with cognition enhancing properties.Acknowledgements
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